Private equity healthcare deals die on reimbursement, compliance, quality, labor, and revenue-cycle integrity — not on growth slides. Use this guide to screen healthcare services and healthtech targets before LOI and run a sharper confirmatory workstream after it.
Healthcare PE due diligence is the structured review of a provider platform, healthcare services business, or healthtech company before a buyout, growth equity check, or platform add-on. Buyers are underwriting cash flows shaped by government and commercial payors, licensed operations, and clinical risk — not a simple B2B software stack.
That changes the kill criteria. A software business with messy sales efficiency can still close. A clinic platform with systemic coding exposure, a pending enforcement action, or a payor that is 60% of revenue cutting rates can destroy entry multiple assumptions before SPA redlines start.
Payer mix (Medicare, Medicaid, commercial, self-pay), rate trends, contract renewals, prior-auth burden, site-of-care shifts, and sensitivity to CMS or state rate cuts.
Fraud-and-abuse exposure (False Claims Act, Anti-Kickback, Stark), HIPAA, state licensing, enrollments, OIG/DOJ signals, and change-of-ownership timelines.
Outcomes metrics, patient safety events, accreditation, physician alignment, referral integrity, and whether quality drives (or threatens) volume and rates.
Clean claim rates, denial trends, coding intensity vs peers, documentation integrity, billing vendors, and AR aging quality for QoE adjustments.
Nursing and clinician wage inflation, agency dependence, provider recruitment/retention, productivity, and capacity constraints that cap the growth thesis.
Corporate practice of medicine structures, MSOs, key-person risk, litigation, real estate/leases, and post-close retention for physicians and clinical leaders.
| Metric / lens | What good looks like (context-dependent) | Red flag |
|---|---|---|
| Payer mix | Diversified; commercial rates support margin thesis | Extreme Medicaid/Medicare with rate cuts pending |
| Same-store volume / visits | Organic growth not only de novo or M&A | Volume down while revenue up via rate/coding only |
| Revenue per encounter | Stable after case-mix explanation | Sharp coding intensity jump without documentation |
| Denial / collection rates | Stable clean-claim and cash collection metrics | Rising denials or AR days without fix plan |
| Quality / outcomes scores | At or above peer benchmarks; improving trend | Safety events, star-rating drops, survey failures |
| Labor cost % of revenue | Controlled agency use; sustainable staffing model | Heavy travelers; wage spiral without price relief |
| Provider concentration | Diversified book of physicians/referrers | Top MD or referral source can break the model |
| Licenses & enrollments | Clean multi-state footprint; transfer path known | Unknown CHOW / enrollment lag risk on timeline |
If the CIM shows EBITDA without a clear bridge to payor rates, volume, and coding integrity, treat the number as marketing until proven. PE models that price healthcare platforms on headline growth without reimbursement and compliance truth overpay systematically.
Traditional healthcare multi-workstream diligence often runs $75K-$300K+ and 4-10 weeks. A structured first-pass public-info pack is $49 per target — or $129 for a 3-Pack shortlist with a comparison PDF.
Order a healthcare PE pack · $39.20 launch → See sample PDFFirst-pass list for buyout screening. Severity tags: Deal-Killer, High, Watch.
| Signal | Severity | Why it matters |
|---|---|---|
| Active government investigation or qui tam | Deal-Killer | Indemnity, escrow, and exit risk can dominate value |
| Single payor above ~40-50% revenue, rate cut path | Deal-Killer | One renewal can break the model |
| Coding intensity jump without documentation story | Deal-Killer / High | Clawbacks and reputation risk |
| Star-rating / survey failure on core facilities | High | Volume, rates, and brand damage |
| Heavy traveler staffing with no wage plan | High | EBITDA is temporary labor arbitrage |
| Unknown Medicare CHOW / license lag | Deal-Killer | Cash flow gap after close |
| Growth only via aggressive utilization | High | Fraud-and-abuse + quality blowback |
| CPOM / MSO structure weakly documented | Deal-Killer | You may not own operable cash flows |
| Approach | Typical cost | Typical time | Best use |
|---|---|---|---|
| Public kill screen + structured pack | $49 / target ($129 3-Pack + comparison PDF) | Minutes to hours | Pre-LOI triage, shortlist ranking |
| Boutique commercial + compliance memo | $25K-$100K | 2-4 weeks | Serious process before exclusivity |
| Full QoE + compliance + clinical stack | $75K-$300K+ | 4-10 weeks | Post-LOI confirmatory |
Use cheap screens to decide which names deserve expensive specialists. Do not reverse the order.
dodilligence delivers institutional-style public-information diligence PDFs for named healthcare targets. Use them to:
Related: Healthcare company library · Sample report · ESG DD guide · Financial DD guide · Legal DD guide · PE teams · Valuation guide
It is the structured review of a healthcare services, provider, or healthtech company before a private equity buyout, growth equity investment, or add-on acquisition. It covers reimbursement, compliance, quality, labor, revenue cycle, and legal/structure risk.
Reimbursement and payer concentration, fraud-and-abuse exposure, quality metrics, labor inflation, coding integrity, and license/enrollment transfer risk.
Public screening: hours to days. Full confirmatory stacks: often 4-10 weeks after LOI.
Active investigations, extreme payor concentration with rate pressure, systemic coding failures, material quality events, and licenses that cannot transfer on timeline.
Specialist stacks often $75K-$300K+. First-pass public-info packs start at $49 per target; 3-Pack shortlist with comparison PDF is $129.
Light public enforcement, quality, and licensing signals: yes. Deep coding audits: usually after LOI access.
It overweights reimbursement mechanics, fraud-and-abuse law, clinical quality, licensed operations, and labor versus plant and inventory.
No. It prioritizes questions and kills weak names early. Specialists still run confirmatory work on finalists.
Each target has a free 1-page brief and a full 20-page PDF diligence report ready to order. Pick a name to start screening.
Institutional PDF pack from public sources. $49/report · $129 3-Pack with comparison PDF · dual legal acceptance at checkout.
Order report → Order 3-Pack → Sample reportScreening frameworks across every active deal sector. Each guide maps to buyable company reports.